• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms

September 27, 2018 | International IgAN Symposium
Myette, et. al.

A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms

James R Myette, Toshiki Kano, Hitoshi Suzuki, Susan E Sloan, Yusuke Suzuki, Brian J G

>SEE POSTER

© 2023 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design